S-1/A: Applied DNA Sciences Files Amendment No. 1 to Form S-1 for Resale of Common Stock Upon Warrant Exercise

Applied DNA Sciences has filed an amendment to its Form S-1 registration statement, pertaining to the resale of up to 41,640,625 shares of common stock issuable upon the exercise of outstanding warrants.

Summary

• Applied DNA Sciences has filed Amendment No.
• 1 to its Form S-1 registration statement with the SEC, concerning the potential resale of up to 41,640,625 shares of its common stock.
• These shares are linked to the exercise of outstanding warrants, including Series C, Series D, and Placement Agent Warrants.
• The warrants were issued in a private placement concurrent with a registered direct offering that closed on October 31, 2024.
• The company will hold a special meeting on January 23, 2025, to seek stockholder approval necessary for the warrants to become exercisable.
• The exercise price for all warrants is $0.32 per share.
• The company will not receive any proceeds from the resale of common stock by the selling stockholders, but will receive proceeds from any cash exercise of the warrants.
• The company intends to use the net proceeds from any cash exercise of the Private Placement Warrants for further development of our Therapeutic DNA Production Services, as well as for working capital and general corporate purposes.
• The last reported sale price of Applied DNA Sciences' common stock on January 8, 2025, was $0.20 per share.
• The company is classified as a smaller reporting company and is exploring strategic alternatives for its DNA Tagging and Security Products and Services business segment, including potential closure or divestiture.

Sentiment

Score: 4

Explanation: The document presents a mixed outlook. While there are potential positives such as the focus on Therapeutic DNA Production Services and cost reduction initiatives, the company faces significant challenges including recurring losses, Nasdaq compliance issues, and uncertainty about its ability to continue as a going concern.

Positives

• Potential influx of capital from warrant exercises could bolster the company's Therapeutic DNA Production Services.
• Focus on Therapeutic DNA Production Services could lead to higher growth and profitability.
• Cost reduction initiatives are expected to lower operating expenses by 15% in fiscal year 2025.
• Appointment of Judith Murrah as President and Clay Shorrock as President of LRx may bring fresh perspectives and leadership.

Negatives

• The company may not receive any proceeds if the warrants are exercised on a cashless basis.
• The company is exploring the potential closure or divestiture of its DNA Tagging and Security Products and Services business segment.
• The company has received a Nasdaq deficiency notification due to non-compliance with the minimum bid price requirement.
• The company has recurring net losses, which have resulted in an accumulated deficit of $309,672,755 as of September 30, 2024.
• There is substantial doubt relating to the company's ability to continue as a going concern.

Risks

• Failure to obtain warrant stockholder approval would prevent the warrants from becoming exercisable.
• The company's common stock price is below Nasdaq's minimum bid price requirement, potentially leading to delisting.
• The company's strategic review may result in the closure or divestiture of business segments, leading to restructuring costs.
• The company's dependence on additional financing raises concerns about its ability to fund operations.
• Stockholders may suffer substantial dilution if certain provisions in the May 2024 Series Warrants and Series D Warrants are utilized.
• There is no guarantee that a commercial demand for the Linea Mpox Virus Assay and/or mpox testing services will develop.

Future Outlook

The company plans to focus on its Therapeutic DNA Production Services, secure commercial-scale supply contracts for LineaDNA IVT templates and Linea RNAP, and develop GMP manufacturing capabilities for LineaDNA.

Management Comments

• The Companys management is currently engaged in a strategic review of the Companys business segments that may result in the closure or divestiture of the Companys DNA Tagging and Security Products and Services and/or MDx Testing Services, as well as workforce reductions and potential management changes.
• Dr. Hayward will continue in his roles as Chief Executive Officer and Chairman of the Board of Directors.

Industry Context

The document highlights the growing market for nucleic acid-based therapeutics, particularly mRNA therapies, and Applied DNA Sciences' strategy to capitalize on this trend through its LineaDNA and Linea IVT platforms.

Comparison to Industry Standards

• The document mentions that as of the third quarter of calendar year 2024, there were 4,099 gene, cell and RNA therapies in development from preclinical through pre-registration stages, almost all of which use DNA in their manufacturing process.
• The document mentions that as of the third quarter of calendar 2024, there were over 450 mRNA therapies under development, with the majority of these therapies (67%) in the preclinical stage (Source: ASGCT Gene, Cell & RNA Therapy Landscape: Q3 2024 Quarterly Report).

Management Changes

Stakeholder Impact

• Shareholders may experience dilution if warrants are exercised.
• Employees may be affected by potential workforce reductions related to the strategic review.
• Customers of the DNA Tagging and Security Products and Services business segment may be impacted by potential closure or divestiture.
• Creditors face increased risk due to the company's financial challenges and going concern uncertainty.

Next Steps

• Hold a special meeting on January 23, 2025, to obtain Warrant Stockholder Approval.
• Implement cost reduction initiatives to achieve a 15% reduction in operating expenses in fiscal year 2025.
• Regain compliance with Nasdaq's minimum bid price rule by May 12, 2025.
• Continue to seek additional working capital through public equity, private equity or debt financings.

Key Dates

Keywords

warrants, common stock, resale, Therapeutic DNA Production Services, DNA Tagging and Security Products and Services, stockholder approval, Nasdaq, LineaDNA, biotechnology, Applied DNA Sciences